TESARO Inc (NDAQ:TSRO) had its price objective decreased by Wedbush from $200.00 to $164.00 in a research note issued to investors on Wednesday. Wedbush currently has an outperform rating on the stock.
Several other research analysts have also recently weighed in on the stock. FBR & Co cut shares of TESARO from an outperform rating to a market perform rating and upped their price target for the company from $151.00 to $202.00 in a report on Thursday, February 16th. Royal Bank of Canada upped their price target on shares of TESARO from $142.00 to $202.00 and gave the company an outperform rating in a report on Friday, February 17th. Leerink Swann cut shares of TESARO from an outperform rating to a mkt perform rating in a report on Friday, February 10th. Finally, Robert W. Baird cut shares of TESARO from an outperform rating to a neutral rating and upped their price target for the company from $127.00 to $182.00 in a report on Monday, February 27th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. TESARO has a consensus rating of Buy and a consensus target price of $187.50.
TESARO (NDAQ:TSRO) opened at 152.05 on Wednesday. The firm’s market capitalization is $8.15 billion. TESARO has a 1-year low of $36.68 and a 1-year high of $192.94. The company has a 50-day moving average of $173.60 and a 200-day moving average of $135.82.
Your IP Address:
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.